Tuesday, October 23, 2018
- 9:00AM-11:00AM
-
Abstract Number: 1998
Autophagy-Related Molecules Detected in Blood and Cartilage Are Biomarkers of Joint Damage in OA
Osteoarthritis and Joint Biology – Basic Science Poster II- 9:00AM-11:00AM
-
Abstract Number: 2418
Awareness of Fertility and Contraception Issues Among Women with Rheumatologic Diseases
Reproductive Issues in Rheumatic Disorders Poster- 9:00AM-11:00AM
-
Abstract Number: 2050
B and T Cell Phenotypes of First Degree Relatives of RA Patients in an Indigenous North American Cohort
Rheumatoid Arthritis – Etiology and Pathogenesis Poster III- 9:00AM-11:00AM
-
Abstract Number: 2124
Bacterial Biofilm Product Curli/Edna Induces NETs and Serum Anti-Curli/Edna Levels Correlate with Bacteriuria and Lupus Activity
Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster III- 9:00AM-11:00AM
-
Abstract Number: 2588
Baseline Pain Severity As a Predictor of Pain Improvement Following Treatment with Tofacitinib in Psoriatic Arthritis
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment- 9:00AM-11:00AM
-
Abstract Number: 1975
Behcet’s Disease Lies in the “B” Holder. New Associations in Disease Susceptibility and Manifestations
Genetics, Genomics and Proteomics Poster- 9:00AM-11:00AM
-
Abstract Number: 2072
Beneficial Effect of Combination Therapy of Etanercept with Non-Steroidal Anti-Inflammatory Drugs Compared to Etanercept Monotherapy in a Spondyloarthritis Animal Model
Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 2537
Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds- 9:00AM-11:00AM
-
Abstract Number: 2511
Benepali Switches in Clinical Practice – a Positive Single Centre Experience
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds- 9:00AM-11:00AM
-
Abstract Number: 2522
Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds- 9:00AM-11:00AM
-
Abstract Number: 2154
Biosimilar Infliximab Treated-Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in France: Characteristics and Clinical Outcomes
Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases- 9:00AM-11:00AM
-
Abstract Number: 2384
Biosimilar Use in Young Adults with Juvenile Idiopathic Arthritis in Germany
Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis- 9:00AM-11:00AM
-
Abstract Number: 2431
Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis